within Pharmacolibrary.Drugs.ATC.R;

model R06AX19_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 8.333333333333334e-06,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0145,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0025,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AX19_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Azelastine is a selective histamine H1 receptor antagonist with additional anti-inflammatory and mast cell stabilizing properties. It is primarily used for the symptomatic relief of allergic rhinitis and conjunctivitis. It is available as a nasal spray and ophthalmic solution, and is approved for use in many countries, including for prescription and over-the-counter use.</p><h4>Pharmacokinetics</h4><p>PK parameters reported for healthy adults after single oral administration.</p><h4>References</h4><ol><li><p>Bernstein, JA (2007). Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. <i>Current medical research and opinion</i> 23(10) 2441–2452. DOI:<a href=\"https://doi.org/10.1185/030079907X226302\">10.1185/030079907X226302</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17723160/\">https://pubmed.ncbi.nlm.nih.gov/17723160</a></p></li><li><p>McTavish, D, &amp; Sorkin, EM (1989). Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. <i>Drugs</i> 38(5) 778–800. DOI:<a href=\"https://doi.org/10.2165/00003495-198938050-00005\">10.2165/00003495-198938050-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2574665/\">https://pubmed.ncbi.nlm.nih.gov/2574665</a></p></li><li><p>Simons, FE, &amp; Simons, KJ (1991). Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. <i>Clinical pharmacokinetics</i> 21(5) 372–393. DOI:<a href=\"https://doi.org/10.2165/00003088-199121050-00005\">10.2165/00003088-199121050-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1685361/\">https://pubmed.ncbi.nlm.nih.gov/1685361</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AX19_1;
